NCT04874194 2025-11-03
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
M.D. Anderson Cancer Center
Phase 1/2 Terminated
M.D. Anderson Cancer Center
Teva Branded Pharmaceutical Products R&D, Inc.
Alliance for Clinical Trials in Oncology
Teva Branded Pharmaceutical Products R&D, Inc.